The Texas Heart Institute presents the 12th Annual Women's Heart and Vascular Symposium May 6, 2023.
Register for our upcoming symposia: texasheart.org/events
0:00 Introduction
1:04 LOWER eGFR IS ASSOCIATED WITH CARDIOVASCULAR EVENTS AND DEATH
2:32 Composite Ranking for Relative Risks by glomerular filtration rate (GFR) and Albuminuria Kidney Disease: Improving Global Outcomes (KDIGO) 2009
4:19 The disease spectrum of MA and its role as an indicator of inflammation
6:04 Number of People Receiving Renal Replacement Therapy Is Projected to Double
10:33 ESKD Outcomes of STOP ACE study
11:33 WHAT ARE THE INNOVATIONS THAT AFFECT T CKD AND CVD EVENTS TODAY
14:37 Adding NS-MRA rationale High residual risk of CKD progression with current therapies
14:59 MR overactivation is a major driver of kidney damage
19:55 FIDELITY: FIGARO-DKD and FIDELIO-DKD investigated the effects of finerenone on kidney and CV outcomes in over 13,000 patients with CKD and T2D¹
22:18 FIDELITY pooled analysis: Effects of finerenone on the components of the 257% eGFR kidney composite outcome
23:25 FIDELITY pooled analysis: Finerenone had consistent effects on CV death and hospitalisation for HF
24:37 Risk of all-cause mortality and CV mortality (primary intention-to-treat analysis and on-treatment analysis)
29:37 Analysis of kidney and CV composite outcomes in those receiving an SGLT2i at baseline and receiving an SGLT2 at any time during the on-treatment period